Boehringer's survodutide shows 16.6% weight loss in phase 3 trial

April 28, 2026 2:00 AM

Zealand Pharma A/S (NASDAQ: ZEAL) announced that Boehringer Ingelheim's survodutide achieved significant weight loss results in a phase 3 clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found